Scully M F, Lane D A, Sagar S, Thomas D P, Kakkar V V
Thromb Haemost. 1977 Feb 28;37(1):162-9.
The fibrinolytic response of 12 patients receiving single daily infusions of 600,000 units of streptokinase (SK) and 90 mg of plasminogen for the treatment of DVT has been studied. The mean plasminogen concentration was maintained throughout the treatment period (4-6 days) at between 20-40% the initial value, while mean circulating plasmin concentration rose to only about twice initial plasma levels. The degradation of fibrinogen as indicated by a fall in clottable fibrinogen did not fall below 1 mg/ml and serum FDP rose to greater than 1 mg/ml. Limited fibrinogenolysis occurred in 2 patients, while in another patient who bled there was immediate and extensive depletion to below 0.5 mg/ml. The beneficial clinical results obtained with this regimen (Kakkar et al. 1975), which produces only limited systemic plasminaemia, suggest that thrombolysis may be facilitated by higher levels of plasminogen than those maintained during conventional SK treatment.
对12例接受每日单次输注60万单位链激酶(SK)和90毫克纤溶酶原治疗深静脉血栓形成(DVT)患者的纤溶反应进行了研究。在整个治疗期间(4 - 6天),平均纤溶酶原浓度维持在初始值的20% - 40%之间,而平均循环纤溶酶浓度仅升至初始血浆水平的约两倍。可凝纤维蛋白原下降所表明的纤维蛋白原降解未降至1毫克/毫升以下,血清纤维蛋白降解产物(FDP)升至大于1毫克/毫升。2例患者发生有限的纤维蛋白原溶解,而在另一例出血患者中,纤维蛋白原立即大量消耗至低于0.5毫克/毫升。该方案(Kakkar等人,1975年)仅产生有限的全身性纤溶血症,却获得了有益的临床结果,这表明比传统SK治疗期间维持的更高水平的纤溶酶原可能有助于溶栓。